2-((4-chlorophenyl)thio)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(dimethylamino)prop-2-en-1-one | 883096-19-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 2-((4-chlorophenyl)thio)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(dimethylamino)prop-2-en-1-one
• 英文别名: 2-(4-Chlorophenyl)sulfanyl-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(dimethylamino)prop-2-en-1-one
• CAS: 883096-19-3
• 化学式: C₁₉H₁₈ClNO₃S
• 分子量: 375.876
• InChiKey: YZGGSNVYIDFZSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  64.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-((4-chlorophenyl)thio)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(dimethylamino)prop-2-en-1-one 在 trans-N,N'-dimethyl-1,2-cyclohexyldiamine 、 potassium phosphate 、 copper(l) iodide 、 一水合肼 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 0.5h， 生成 4-((4-chlorophenyl)thio)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-phenyl-1H-pyrazole
  参考文献：
  名称：

  Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain

  摘要：

  We report herein the identification of MK-4409, a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. Starting from a high throughput screening (HTS) hit, medicinal chemistry efforts focused on optimizing of FAAH inhibition in vitro potency, improving the pharmacokinetic (PK) profile, and increasing in vivo efficacy in rodent inflammatory and neuropathic pain assays.

  DOI：

  10.1021/ml5001239
• 作为产物：
  描述：

  2-溴-1-(2,3-二氢-1,4-苯并二氧)乙酮 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.67h， 生成 2-((4-chlorophenyl)thio)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(dimethylamino)prop-2-en-1-one
  参考文献：
  名称：

  Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain

  摘要：

  We report herein the identification of MK-4409, a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. Starting from a high throughput screening (HTS) hit, medicinal chemistry efforts focused on optimizing of FAAH inhibition in vitro potency, improving the pharmacokinetic (PK) profile, and increasing in vivo efficacy in rodent inflammatory and neuropathic pain assays.

  DOI：

  10.1021/ml5001239

文献信息

• Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain
  作者：Harry R. Chobanian、Yan Guo、Ping Liu、Marc D. Chioda、Selena Fung、Thomas J. Lanza、Linda Chang、Raman K. Bakshi、James P. Dellureficio、Qingmei Hong、Mark McLaughlin、Kevin M. Belyk、Shane W. Krska、Amanda K. Makarewicz、Elliot J. Martel、Joseph F. Leone、Lisa Frey、Bindhu Karanam、Maria Madeira、Raul Alvaro、Joyce Shuman、Gino Salituro、Jenna L. Terebetski、Nina Jochnowitz、Shruti Mistry、Erin McGowan、Richard Hajdu、Mark Rosenbach、Catherine Abbadie、Jessica P. Alexander、Lin-Lin Shiao、Kathleen M. Sullivan、Ravi P. Nargund、Matthew J. Wyvratt、Linus S. Lin、Robert J. DeVita

  DOI：10.1021/ml5001239

  日期：2014.6.12

  We report herein the identification of MK-4409, a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. Starting from a high throughput screening (HTS) hit, medicinal chemistry efforts focused on optimizing of FAAH inhibition in vitro potency, improving the pharmacokinetic (PK) profile, and increasing in vivo efficacy in rodent inflammatory and neuropathic pain assays.